| Secondary prevention of HAPE in a Mount Everest summiteer. | |
| | |
MedLine Citation:
|
PMID: 19775220 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Climbers who have suffered a previous episode of high altitude pulmonary edema (HAPE) are at significantly increased risk of developing it again on return to high altitude. In spite of the high mortality associated with HAPE, some climbers are willing to take this risk in order to summit the tallest mountains in the world. This is a case report of a climber who suffered an episode of HAPE partway up Mount Everest. He was determined to complete his summit attempt that same climbing season, which would involve a return to extreme altitude less than 3 weeks following recovery. Based on experimental evidence suggesting that sildenafil, salmeterol, and acetazolamide may have therapeutic value for both the prevention and treatment of HAPE, he used these medications for secondary prevention. He was able to successfully reach the summit of Mount Everest and return to base camp without any evidence of recurrence of pulmonary edema. This provides clinical evidence that medication can be used to increase the safety margin for HAPE-susceptible individuals traveling to extremely high altitudes. |
| | |
Authors:
|
Ola Dunin-Bell; Suzanne Boyle |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: High altitude medicine & biology Volume: 10 ISSN: 1557-8682 ISO Abbreviation: High Alt. Med. Biol. Publication Date: 2009 |
Date Detail:
|
Created Date: 2009-09-24 Completed Date: 2009-12-22 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100901183 Medline TA: High Alt Med Biol Country: United States |
Other Details:
|
Languages: eng Pagination: 293-6 Citation Subset: IM; S |
Affiliation:
|
McMaster University, Hamilton, Ontario, Canada. oladuninbell@me.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acetazolamide
/
therapeutic use Adult Albuterol / analogs & derivatives, therapeutic use Altitude* Bronchodilator Agents / therapeutic use Diuretics / therapeutic use Humans Male Mountaineering* Piperazines / therapeutic use Pulmonary Edema / prevention & control* Purines / therapeutic use Recurrence / prevention & control Sulfones / therapeutic use Vasodilator Agents / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Bronchodilator Agents; 0/Diuretics; 0/Piperazines; 0/Purines; 0/Sulfones; 0/Vasodilator Agents; 139755-83-2/sildenafil; 18559-94-9/Albuterol; 59-66-5/Acetazolamide; 89365-50-4/salmeterol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hyperoxygenated solution: effects on acute hypobaric hypoxia-induced oxidative damage in rabbits.
Next Document: Expression of angiopoietin-like 4 and tenascin C but not cathepsin C mRNA predicts prognosis of oral...